Immunotoxins Market Size To Reach $243.3 Million By 2030

December 2024 | Report Format: Electronic (PDF)

Immunotoxins Market Growth & Trends

The global immunotoxins market size is expected to reach USD 243.3 million by 2030, registering a CAGR of 8.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

key Request a free sample copy or view report summary: Immunotoxins Market Report

Immunotoxins Market Report Highlights

Based on product, Diphtheria Toxin (DT) segment dominated the product segment in the market with a market share of 43.91% in 2024. Diphtheria toxin has been used in cancer treatment as part of targeted therapies designed to attack cancer cells.
Based on application, Therapy development is driving the growth of the market and is expected to see the fastest growth rate of 8.29% during the forecast period. This growth is driven by increasing investment in R&D, particularly in targeted cancer therapies, which offer more precise and effective treatment options.
Based on end-use, Pharmaceutical and biotechnology companies are leading the immunotoxins market with a market share of 46.49% in 2024. This is mainly due to their significant investment in research and development to create new immunotoxins tailored for specific medical conditions.
Based on region, North America immunotoxins market dominated the market and accounted for 41.45% share in 2024, attributed to the region’s advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for immunology and oncology research.